METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours

Mostrar otras versiones (1)

BACKGROUND: Preclinical studies have suggested that metformin has anti-tumour effects, likely due to blockage of mammalian target of rapamycin pathway through adenosine monophosphate-activated protein kinase and decreased insulin levels. A retrospective study showed that metformin added to everolimu...

Descripción completa

Detalles Bibliográficos
Autores principales: Glasberg, João, Talans, Aley, Giollo, Thomás Rivelli, Recchimuzzi, Débora Zachello, Neto, João Evangelista Bezerra, Lopez, Rossana Veronica Mendonza, Hoff, Paulo Marcelo Gehm, Riechelmann, Rachel P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2022
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085158/
https://www.ncbi.nlm.nih.gov/pubmed/35685961
http://dx.doi.org/10.3332/ecancer.2022.1369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085158/
https://www.ncbi.nlm.nih.gov/pubmed/35685961
http://dx.doi.org/10.3332/ecancer.2022.1369

Ejemplares similares